Key Takeaways
- Gross margin was the quarter's hero: Jumped to 47.5% from 40.9% QoQ as raw material costs fell and a new ERP system tightened inventory controls, with management calling this "just the beginning."
- FY27 guidance raised across the board: Revenue to "very, very comfortably" cross ₹750 crores and EBITDA margin to land comfortably above the ~17% promised, driven by the margin recovery and a strong H2 pipeline.
- The building year is nearly built: Unit III expansion starts in December, the Adelaide facility targets a January 2027 commissioning, and two acquisitions closed, setting the stage for a FY28 where "the results of that building should start to show."
- Receivables and cash flow are the near-term watchpoints: Receivables swelled to ~₹250 crores on late-quarter sales and slower payments from the two largest export customers; negative H1 operating cash flow was driven by an OFS payment and a payables unwind.
- What to watch next quarter: Whether receivables normalize as promised, the first third-party R&D contracts from Sai Prathyak, and the FY28 guidance drop in the Jan/Feb call.
Gross Margin & Profitability
- Raw material tailwind: Raw material cost fell ~3% even as revenue grew 9%, a combination management attributed to working through higher-cost inventory, introducing strict FIFO controls, and implementing a new ERP system that brought inventory levels down materially.
- Operating leverage kicked in: Employee and other operating costs together rose by less than 6%, so most of the gross margin gain of ~660 bps flowed through to EBITDA, which grew 67.4% sequentially to ₹41.4 crores.
- Depreciation spike absorbed: Depreciation and amortization tripled to ₹25.1 crores from ₹8.1 crores in Q1, reflecting capitalization of Noumed assets and amortization of molecules acquired from Sai Prathyak Laboratories. PAT still grew 32.7% to ₹10.5 crores because PBT was in line with Q1 and a tax credit of ₹0.6 crores was recorded.
- Margin commitment: Management expects to keep gross margin above 45% in all coming quarters and says the inventory management improvements are "just the beginning" and will be worked through a lot in the next 2–3 quarters.
Anil Kumar Karusala: "This quarter was, the gross margin was the hero of this, this quarter, according to me. As I said to you in my opening remarks, we have worked very thoroughly on the inventory management, and it's just the beginning. We are going to work through that a lot in the next two, three quarters."
Revenue Build & Export Mix
- H1 ahead of the 45:55 plan: H1 revenue of ₹376 crores is ahead of the guided split, with Q4 historically the strongest quarter, giving management confidence to raise the full-year target.
- Australia share normalized: Australia fell to 76% of export revenue from 83% in Q1 because Q1 was elevated when Sai stepped in with additional volumes for Noumed after third-party contract manufacturers fell short; Q2 returned to the planned ~70:30 Australia-to-other-markets pattern.
- Philippines is the growth engine: Philippines rose to 16% of export revenue from 12% in Q1, driven by the addition of 11 molecules and 22 SKUs during the quarter, led by cardiovascular therapies including telmisartan-amlodipine, sacubitril-valsartan, and rosuvastatin.
- Two Philippines contracts in motion: The existing USD 1.4 crore contract added 11 molecules this quarter, while the anti-TB contract (USD 1.1 crore) has completed validation batches with commercials to start after January 2027.
- Wesfarmers renewal locked in: A 3-year OTC medicine supply contract with Wesfarmers (Priceline, Pharmacy Health) was renewed on 25 August 2026, valued at AUD 3 crores (~₹204 crores), with an expanded product portfolio and higher agreement value than the one it replaced.
Mark Thulborne: "These are renewals earned through years of consistency and delivering in one of the most tightly regulated markets in the world."
Capacity Expansion & Capex Cycle
- Unit III expansion near completion: A new block commences from December 2026, adding high-capacity ointment manufacturing, a dedicated high-speed capsule filling line, and high-speed liquid oral manufacturing and filling lines. Most of the additional volume is directed to Australia and New Zealand, with "a lot of margins coming from there, from Q4."
- Adelaide facility timeline: Commissioning expected January 2027, slightly behind previous guidance due to logistics disruptions from the Iran conflict; TGA license inspection anticipated Q2 2027; commercial supply to commence thereafter upon license grant.
- Adelaide economics: Once onshore manufacturing is underway, outsourced packing moves in-house, enhancing distribution margin toward a manufacturing margin on the same contracted revenue; inventory reduces from 9–10 months to 5–6 months, freeing warehouse space and working capital; supply chain to pharmacy partners becomes more reliable.
- Bulk tablet bridge: In Q4 FY27, while Adelaide prepares to start production, Sai will supply bulk tablets from India to support it.
- Saicriti injectable facility: Targeting completion July 2027, with accreditation within ~12 months of completion; exports from FY28 and Europe from FY29. The facility is built to US FDA standards but the prime market focus for the next two to three years is EU GMP, Southeast Asia, Latin America, and the Middle East.
- Debt peaks this year: FY27 will be the peak debt year as the capex program completes; debt is expected to come down from FY28 and FY29 as assets start earning. Saicriti project debt will be raised and sit at the subsidiary level, drawn as construction progresses.
Anil Kumar Karusala: "FY27 remains a year of building, and FY28 is when the results of that building should start to show in our performance."
Acquisitions & R&D Build-out
- Saicriti Pharma acquisition completed: Investment of ₹83.83 crores for a 60% stake completed; shareholders approved variation in use of IPO proceeds.
- Sai Prathyak Laboratories acquired: 60% stake acquired on 15 September 2026 for ₹15 crores; renamed Sai Prathyak Laboratories; now the dedicated R&D subsidiary with all group R&D consolidated there. The residual 40% may be acquired through a right of first refusal at the same valuation.
- Sai Prathyak's dual role: It will serve as the in-house R&D center for both Noumed and Sai, plugging the R&D gap in the next two to three quarters, and will also offer third-party CDMO and CRO services as a revenue model.
- Third-party revenue timeline: Beginning to sign R&D and CRO development contracts with external clients from Q3 FY27; revenue generation projected from FY28, with long-term agreements. Revenue and earnings guidance to be provided in the next quarter earnings call.
- SP Analytics stake: Board approved acquisition of the balance 25% stake in SP Analytics Private Limited; on completion it becomes a wholly owned subsidiary.
- In-house pipeline: 76 products under development targeted for FY28.
Anil Kumar Karusala: "It's a self-sufficient and it becomes a revenue model, cost center revenue model."
Balance Sheet & Cash Flow
- Receivables swelled to ~₹250 crores: Driven by two factors: sales increased in the last 1–1.5 months of the quarter so amounts were not yet due, and the two biggest export customers were on the lower side in payments. Normalization expected in Q3 and Q4.
- Aging profile: Export receivables aging is always less than 120 days; domestic branded generic receivables currently at 130–150 days, targeted to reduce to less than 120 days across the board in the next 2–3 quarters.
- Negative H1 operating cash flow: Majorly driven by a ₹113.1 crore OFS payment (decrease in other financial liabilities) and almost ₹49 crore decrease in payables, current liabilities, and trade payables. An analyst questioned the cyclicality mechanism; management cited the difference in scale and subsidiaries versus the prior year, and the analyst said they would relook into it and connect later.
- Other income restatement: From Q2, other income is presented below EBITDA; prior periods restated; Q1 FY27 EBITDA restated to ₹24.7 crores at a 13.7% margin from ₹27.3 crores at 14.9%; PBT and PAT unchanged.
Management Bandwidth & Strategic Direction
- Senior management ramp-up: Expenses on people and management have increased very high in the last two quarters compared to last year; senior management under KMP substantially increased in the last six to eight months, with a further substantial increase expected in the next three months to four months.
- CEO role shift: The CEO is preparing the entire team at all levels across Saicriti and Sai Australia and wants to focus more on strategy, not everyday business.
- Three-year vision: By the end of three years, Sai Pratik will have formidable manufacturing facilities covering all dosage forms including onco, tablets, and mAbs, with backward integration, in-house product development, and differentiated products. By the end of 2030, when all facilities are in full force, Sai is expected to be a technology company with development, backward integration, and forward integration.
- Biosimilars and mAbs: A plan of action is being prepared, with a paper to be released in a month; rolling map and planning done with project management consultants; to be taken to the board for approval; will be for global markets. Management declined to provide specifics until board approval and public disclosure.
- US FDA stance: No plans to launch into the US FDA for at least two to three years, but the option is kept open if a CMO client wants to manufacture at the site.
Anil Kumar Karusala: "I'm preparing the entire team at all levels, be it at Saicriti, be it at Sai Australia. We're doing everything to ramp up the bandwidth of the management, to take up the individual responsibilities. And I myself want to focus more on the strategy, not on everyday business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue | "Very, very comfortably" cross ₹750 crores | FY27 full year |
| FY27 EBITDA margin | Comfortably above ~17% | FY27 full year |
| Gross margin floor | Above 45% in all coming quarters | All coming quarters |
| Unit III expansion | New block commences; most additional volume to Australia/NZ | December 2026 |
| Adelaide facility commissioning | Commissioning; TGA inspection in Q2 FY27; commercial supply after license grant | January 2027 |
| Saicriti facility completion | Completion; accreditation within ~12 months; exports from FY28, Europe from FY29 | July 2027 |
| Sai Prathyak third-party contracts | Begin signing R&D/CRO contracts; revenue from FY28 | Q3 FY27 |
| Domestic branded generic receivables | Reduce to less than 120 days across the board | Next 2–3 quarters |
| Philippines anti-TB contract | Commercials start | After January 2027 |
| FY28 guidance release | Full FY28 guidance provided | Next earnings call (Jan/Feb) |
| US FDA launch | No launch for at least 2–3 years; option open for CMO clients | At least 2–3 years |
| Debt trajectory | FY27 peak debt year; debt to come down from FY28/FY29 | FY28 onward |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹196.1 cr, +9% QoQ |
| H1 FY27 revenue | ₹376.0 cr, ~50% of FY27 target of ₹750 cr |
| Gross margin | 47.5%, up from 40.9% in Q1 FY27 |
| EBITDA | ₹41.4 cr, +67.4% QoQ |
| EBITDA margin | 21.1%, up from 13.7% in Q1 FY27 (restated) |
| H1 FY27 EBITDA margin | 17.6%, ahead of ~17% full-year guidance |
| Profit after tax | ₹10.5 cr, +32.7% QoQ; PAT margin 5.4% |
| H1 FY27 PAT | ₹18.4 cr |
| Depreciation and amortization | ₹25.1 cr, up from ₹8.1 cr in Q1 FY27 |
| Finance cost | ₹9 cr, down from ₹9.4 cr in Q1 FY27 |
| Total borrowings | ₹357 cr at 30 Sep 2026, vs ~₹320 cr at Mar 2026 |
| Cash and cash equivalents | ₹129 cr at 30 Sep 2026 |
| CDMO share of revenue | ~73% of Q2 revenue; branded generics ~27% |
| Exports share of revenue | ~73% of Q2 revenue |
| Australia share of export revenue | 76%, vs 83% in Q1 FY27 |
| Philippines share of export revenue | 16%, up from 12% in Q1 FY27 |
| Receivables | ~₹250 cr in H1 FY27; export/CDMO aging <120 days, domestic branded generics 130–150 days |
| Noumed contracted Australia OTC supply | AUD 23.2 cr (~₹1,506 cr), across EBOS and Wesfarmers renewals |
| Saicriti injectable capacity target | ~15.47 cr units, ~47% more than Units I & II upgrade would have delivered |
| Unit III capacity increase | 81%, from 8.55 cr to 15.5 cr units per month |
| Sai Prathyak molecules and SKUs | 174 molecules, 285 SKUs across critical care and oncology |
| In-house dossiers | 98 developed, 45 commercialized, 76 under development for FY28 |